Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

Inclusion Criteria

• •Able to comprehend and sign an IRB approved Informed Consent Form
• •Male or female 18 years of age or older
• •Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted contraceptive, double barrier birth control, or an intrauterine device (IUD) and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment and during the course of the study
• •Previously received and tolerated panitumumab treatment on studies 20020374 Part 2 or 20030138/20040116
• •Is considered "stable" or "responding" based on the RECIST (20020374 Part 2) or WHO (20040116) criteria, at the final treatment visit of the previous panitumumab clinical trial and the screening visit for this study
• •No more than 2 months (60 days) have elapsed since the final treatment visit of the previous panitumumab clinical trial
• •Karnofsky score \> or = 70%
• •Known to be HIV positive
• •History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study drug administration
• •Allergy to the ingredients of the study medication or to Staphylococcus Protein A
• •History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis